Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

According to the Dickerson’s Pharmacy mission, they are “Saving patients time and money and cherishing friendships in Bladen ...

Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country's first trade surplus in energy ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...